Drug Discovery Startup ArrePath Scores $20 Million & More Digital Health Funding

Start up drug discovery ArrePath announced Thursday that it has raised $20 million in an seed funding round led by the Boehringer Ingelheim Venture Fund, Insight Partners and Innospark Ventures.

Other participants in the round include Viva BioInnovator, Arimed Capital, PTX Capital and Nor’easter Ventures. The company, which focuses on developing new types of anti-infective drugs for the best antimicrobial resistance, plans to use the investment to support its machine learning-based drug discovery platform.

ArrePath also appointed Dr. Lloyd Payne as president and CEO. Payne most recently served as Executive Vice President, Head of Anti-Infectives, at German drug discovery company Evotec.

“This funding is a strong vote of confidence, by a global investment syndicate, in our platform and its tremendous potential in anti-infective drug discovery,” Payne said in a statement. “The funding will enable the advancement of our initial leads and expansion of our discovery efforts, as well as the improvement of our imaging platform and the application of machine learning in the discovery of new drugs to address critical global health challenges.”

Rupa HealthThat a platform offers providers to order a variety of laboratory tests and get results, scored $ 20 million in a series of financing.

The round was led by Bessemer Ventures with the participation of existing investors including First Round Capital, Lachy Groom, SV Angel, Floodgate, Hustle Fund, Operator Collective, the Chainsmokers, Jared Leto and Joe Montana.

In a Posting on the company’s website, CEO and co-founder Tara Viswanathan said the platform allows providers to order traditional labs alongside other tests developed by independent companies, such as microbiome assays, that may be more difficult to access.

CancerIQ announced it had raised $14 million in Series B financing around LED by Merck Global Health Innovation Fund and Amgen Ventures. Other participants include McKesson Ventures, OSF Ventures and HealthX Ventures.

Embedded in an EHR, the startup’s platform helps healthcare providers determine an individual patient’s cancer risk based on family history, genetics, health behaviors, and other factors. It can also send patients down different healthcare paths, depending on the results, such as displays, vaccinations and lifestyle changes.

CancerIQ scored $4.8 million in Series A funding in 2020.

“CancerIQ’s vision is to end cancer as we know it by eliminating health inequalities and democratizing access to the latest advances in early cancer detection and prevention,” said co-founder and CEO Feyi Olopade Ayodele in a statement.

“We have started to make genetic testing more accessible and connect patients to the right preventive services at the right time. This latest round of funding will help CancerIQ reach more patients and connect with more innovations that promise to transform cancer from a deadly disease to a manageable condition.”

Dawn Healtha digital mental health company for children and teens, targeting schools, has raised $10 million in funding, according to the series axios

The round was led by Lightspeed Venture Partners, with participation from Maven Ventures and individual investors. The round comes about a year after the company A $1.8 million seed round.

Daybreak plans to use the funding to expand across the country and focus on health equity.

July, an AI-powered app that tracks metrics such as activity, sleep, lab results, EHR data, and weather to help users manage chronic conditions, has raised $3.8 million in seed funding.

The round was led by SpeedInvest and Norrken VC, with participation in Softbank’s Vision Fund and Dieter Von Holtzbrinck Ventures.

“July helps patients, healthcare providers and employers identify behavioral triggers that exacerbate or improve the most difficult-to-treat and complex chronic conditions, including asthma, migraines, depression and bipolar disorder,” CEO and co-founder Bettina Hein said in a statement. “With the support of Speedinvest, Norrsken and our other investors, we can expand our reach to improve patient health and lower healthcare costs.”